Jeffrey Rathmell named chair of the UChicago Ben May Department for Cancer Research, director of Ludwig Center for Metastasis Research

Immunai to collaborate with Teva to enhance clinical decision making in immuno-oncology clinical trials

Immunai Inc. announced a multi-year collaboration with Teva Pharmaceuticals, an affiliate of Teva Pharmaceutical Industries Ltd. Under the agreement, Immunai will collaborate with Teva in immunology and Immuno-oncology programs.

November 22, 2024

Vol.50 No.44

Clinical Roundup

Kidney cancers rely on mitochondrial metabolism to metastasize, UTSW study shows

Research from Children’s Medical Center Research Institute at UT Southwestern shows that metastatic kidney cancers rely heavily on mitochondrial metabolism. These findings are contrary to how tumors operate while still in the kidney.

September 06, 2024

Vol.50 No.33

In Brief

Glen Barber named director of Center for Innate Immunity and Inflammation at Ohio State’s Pelotonia Institute for Immuno-Oncology

Glen Barber was named director of the Center for Innate Immunity and Inflammation within the Pelotonia Institute for Immuno-Oncology at the Ohio State University Comprehensive Cancer Center—James Cancer Hospital and Solove Research Institute.

July 12, 2024

Vol.50 No.28

In Brief

Linda Liau elected to Taiwan’s Academia Sinica

Linda Liau, chair of neurosurgery at the David Geffen School of Medicine at UCLA, was elected as an Academician of Academia Sinica by the 35th Convocation of Academicians, the preeminent academic institution in Taiwan.

July 12, 2024

Vol.50 No.28

Clinical Roundup

NLRC5 is an innate immune sensor that plays a crucial role in PANoptotic cell death

NLRC5 plays a previously unknown role as an innate immune sensor, triggering cell death, according to new research from St. Jude Children’s Research Hospital. The findings, published in Cell, show how NLRC5 drives PANoptosis, a prominent type of inflammatory cell death.

June 21, 2024

Vol.50 No.25

Clinical Roundup

Enhertu demonstrated median PFS of 13.2 months in IHC 1+ or IHC 2+/ISH- metastatic breast cancer in phase III trial

Detailed positive results from the DESTINY-Breast06 phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in patients with HR-positive, HER2-low metastatic breast cancer and the overall trial population (patients with HR-positive, HER2-low and HER2-ultralow [defined as IHC 0 with membrane staining] expression) following one or more lines of endocrine therapy.

June 07, 2024

Vol.50 No.23

Jeffrey Rathmell named chair of the UChicago Ben May Department for Cancer Research, director of Ludwig Center for Metastasis Research

YOU MAY BE INTERESTED IN

Immunai to collaborate with Teva to enhance clinical decision making in immuno-oncology clinical trials

Kidney cancers rely on mitochondrial metabolism to metastasize, UTSW study shows

Glen Barber named director of Center for Innate Immunity and Inflammation at Ohio State’s Pelotonia Institute for Immuno-Oncology

Linda Liau elected to Taiwan’s Academia Sinica

NLRC5 is an innate immune sensor that plays a crucial role in PANoptotic cell death

Enhertu demonstrated median PFS of 13.2 months in IHC 1+ or IHC 2+/ISH- metastatic breast cancer in phase III trial

Renew today!

Subscriber content

Never miss an issue!

Login